ArticleNPJ breast cancer2025
Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redefining breast cancer: therapeutic opportunities in HER2-low and emerging molecular subtypes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Clinicopathological characteristics across the HER2 expression spectrum in invasive breast carcinoma of no special type: a single-centre retrospective study.Diagnostic pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the representativeness of HER2-low and ultralow status in core needle biopsies (CNB) with AI assistance and investigate the clinicopathological and molecular characteristics of HER2-ultralow, HER2-null, and HER2-low breast cancer patients in the Chinese population. CNB-surgical excision biopsy (SEB) concordance was high between HER2-null and ultralow/low groups but limited in the ultralow subgroup. Univariate analyses showed that TNBC subtype, HR negative expression, high Ki-67 index, and AR negative expression were potential indicative factors for the discordance of HER2 status between CNB and SEB. Clinicopathological features showed no significant differences between low and ultralow groups. Genomic analysis revealed subtle mutation pattern differences. The HER2 copy number level did not show additional value in distinguishing subgroups. Conclusions highlight the need to address CNB-SEB diagnostic discordance, particularly in ultralow cases, emphasizing the necessity of HER2 retesting in surgical specimens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.